Berge Melkonian

Sr. Director, Commercial Excellence at Optinose

Berge Melkonian has a diverse work experience spanning different industries. Berge currently holds the position of Sr. Director, Commercial Excellence at Optinose since January 2023. Prior to this, they worked at Aimmune Therapeutics as Sr Director, Payer Marketing / Market Access Marketing from December 2020 to February 2023. Berge spent a significant portion of their career at Boehringer Ingelheim, where they held various roles including CV Marketing, Market Access Marketing, Innovative Customer Solutions Steering Committee Lead and CPI, and Specialty Sales Leader for Cardiovascular Portfolio. Berge was responsible for leading and mentoring a successful sales team, developing innovative strategies, establishing a culture of teamwork, and driving sales growth. Before joining Boehringer Ingelheim, Berge worked at Boehringer Ingelheim Pharmaceutical as a Primary Care, Specialty, Health System, Account Sales Rep and Manager. Berge started their career as a Software Engineer and Computer Programmer at FALA.

Berge Melkonian has a diverse education background with a focus on various disciplines. In 1994-1996, they attended Nassau Community College, where they earned an AS degree in Math and Science, as well as Humanities. Following that, from 1997 to 1999, they studied at Stony Brook University and obtained a Bachelor of Science degree in Biology. Moving forward, between 1999 and 2001, they attended St. John's University and received a Bachelor of Science degree in Computer Science, Software Engineering, and Business.

Later, in 2008 and 2009, Berge enrolled at the University of the Sciences in Philadelphia and pursued an MBA degree in Pharmaceutical Business.

In addition to their formal education, Berge Melkonian has also obtained various certifications. Berge acquired Six Sigma certifications from Boehringer Ingelheim in October 2018. Furthermore, they completed the Digital Marketing Professional Certificate Program but the specific details of the institution and completion date are not mentioned in the information provided.

Links

Previous companies

Aimmune Therapeutics logo
Boehringer Ingelheim logo